強勢推廣 歡迎下載

全球用於臨牀治療阿爾茨海默病的藥物目前只有寥寥數款，在17年沒有新藥上市後，最近中國原創治療阿爾茨海默病新藥率先獲批。

11月2日國家藥品監督管理局有條件批准了甘露特鈉膠囊（商品名“九期一”）上市註冊申請。

而中國原創治療阿爾茨海默病新藥率先獲批上市，不僅填補世界空白，也引發了外媒關注。

Authorities in China have approved a drug for the treatment of Alzheimer's disease, the first new medicine with the potential to treat the cognitive disorder in 17 years.

中國已經批准了一種用於治療阿爾茨海默病的新藥物，這是17年來首個獲批，可能可以治療認知障礙疾病的新藥。

The seaweed-based drug, called Oligomannate, can be used for the treatment of mild to moderate Alzheimer's.

這個海藻中提取有效物質的新藥，可改善輕、中度阿爾茨海默病患者認知功能障礙。

China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years Via CNN

研發團隊在《細胞研究》（Cell Research）雜誌上發表論文，揭示了GV-971抑制阿爾茨海默症的作用機理和海藻有關。

In September, the team behind the new drug, led by Geng Meiyu at the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, said they were inspired to look into seaweed due to the relatively low incidence of Alzheimer's among people who consume it regularly.

今年9月，中國科學院上海藥物研究耿美玉帶領的研發團隊稱，他們受到啓發，研究海藻和老年癡呆症的關聯。因爲經常食用海帶和海藻一類食物的人，發生阿爾茨海默病的概率相對較低。

In a paper in the journal Cell Research, Geng's team described how a sugar contained within seaweed suppresses certain bacteria contained in the gut which can cause neural degeneration and inflammation of the brain, leading to Alzheimer's.

發佈在《細胞研究》上的論文揭示了從海藻中提取的一種糖類分子可以抑制一種腸道菌羣，這種菌羣會導致神經病變和腦部炎症，從而引發阿爾茨海默病。

China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years Via CNN

另據每日經濟新聞報道，綠谷製藥方面表示，公司已做好生產、銷售的各項準備，藥品年內投放市場。

The company said Oligomannate will be available in China "very soon," and it is currently seeking approval to market it abroad, with plans to launch third-phase clinical trials in the US and Europe in early 2020.

該公司表示甘露特鈉膠囊將會“很快”在中國上市，目前正尋求批准在國外銷售，並計劃於2020年初在美國和歐洲啓動第三階段臨牀試驗。

China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years Via CNN

目前全球約有5000萬阿爾茲海默患者，中國患者約佔20%。阿爾茨海默病是以1906年發現這種疾病的神經病理學家Alois Alzheimer的名字命名的。到目前爲止，世界範圍內製藥公司的研究進展緩慢。

In October, US pharmaceutical giant Biogen said it would pursue Food and Drug Administration (FDA) approval for an experimental treatment called aducanumab, after announcing in March it was canceling a large clinical trial for the drug.

美國製藥巨頭百健公司也在研發一種叫aducanumab的阿爾茨海默病治療藥物。繼3月宣佈將臨牀試驗後不理想後，今年10月，百健公司宣佈實驗獲得進展，將尋求美國食品和藥物管理局（FDA）獲批新藥。

Johnson & Johnson, Merck, Pfizer and Eli Lilly have all previously abandoned projects to develop a drug for Alzheimer's after unsatisfactory clinical data.

此前由於臨牀數據不理想，強生、默克、輝瑞和禮來等公司都放棄了阿爾茨海默病藥物的研發項目。

China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years Via CNN

外國網友紛紛爲中國科研人員的創新成果點贊：

Ok American doctors stay looking into it. Remember some of our medicines they discovered first.

好吧，美國的醫生看看。記得有些藥是他們（中國）先研製的。

Thousands of attempts have resulted on this drug. Hopefully, it will cure the patient in an expected way.

無數次努力嘗試纔有了這款新藥的誕生，希望可以對患者有效。

Amazing! So what have we been doing? Of course big pharmaceutical wants to make every penny from the sick.

太棒了！所以看看我們做了些啥？各大醫藥公司只想着從患者身上賺取更多的錢。

圖文：CNN，Twitter, 每日經濟新聞